Total Funding
37
75
Total FundingGrant raised
Growth Score
-6 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
166310
Facile Therapeutics is a biotechnology company that develops therapeutic drugs for clostridium difficile infection.
- Matthew Bogyo: Founder and Head of Scientific Advisory Board
- Marc Navre: CEO and Co-Founder
About the Company
Facile Therapeutics is a biotechnology company that develops therapeutic drugs for clostridium difficile infection. The company demonstrated Ebselen, an anti-toxin that doesn't cause the death of healthy gut bacteria that makes the colon resistant to C diff reinfection.
Facile Therapeutics was founded in 2017 by Marc Navre and Matthew Bogyo
and is based in Belmont, California.
